(Lenght of Discussion: 14 min)


Tom Keane reviews three key presentations from the most recent American Urological Association (AUA) 2018 meeting.  Among the presentations Keane discusses is a prostate cancer Imaging presentation by the Chief of MRI and Nuclear Medicine at the San Francisco VA Medical Center, Thomas Hope, MD. During his presentation, Prostate Cancer: What PET to GET? Hope discussed the different PET radiotracers available today for prostate cancer including NaF PET/CT, Choline, Fluciclovine, Ga-68 PSMA-11 prostate specific membrane antigen, and PyL compound. 

The second presentation Keane reviews is by Eric Small on Patient Reported Outcomes following the SPARTAN trial. He highlights health-related quality of life outcomes with the addition of Apalutimde to ADT and significantly improved MFS in the M0CRPC patient population.

The last presentation Keane reviews are the Comparative Genomic Analysis of African American and Non-African American Prostate Cancers: A Report from the Decipher GRID Collaborative, a presentation by Walter Rayford, MD, from The Urology Group in Memphis, TN. Keane highlights the focus if the presentation, racial disparities in prostate cancer incidence and mortality.

Thomas E. Keane, MBBCh, FRCSI, FACS

Presentations References in this Discussion:
Prostate Cancer: What PET to GET?

Patient Reported Outcomes in SPARTAN, a Phase 3, Double-Blind, Randomized Study of Apalutamide plus ADT vs placebo plus ADT in Men with nmCRPC

Comparative Genomic Analysis of African American and Non-African American Prostate Cancers: A Report from the Decipher GRID Collaborative